Exclusive Summary

• • UB609 is a fully synthetic GLP-1 analogue engineered to enhance peptide stability through the incorporation of non-natural amino acids.
• • In rats, the oral bioavailability of UB609 is approximately tenfold that of Semaglutide, with a half-life twice as long. Therefore, if administered three times per week, the cost of oral UB609 is expected to be substantially lower (due to reduced active pharmaceutical ingredient requirements) compared to Rybelsus® (one of the once-daily oral Semaglutide tablets for weight loss).
• • UB609 is a novel drug candidate that, relative to existing subcutaneous (SQ) anti-obesity agents such as Semaglutide and Tirzepatide, offers a longer half-life with comparable efficacy in weight reduction. This indicates that UB609 may require less frequent dosing than current subcutaneous anti-obesity drugs.

Asset Materials

Contact Us for Full Materials